版本:
中国

BRIEF-FDA accepts the Biologics' license application for Avelumab for priority review

Nov 29 Pfizer Inc

* FDA accepts the biologics license application for Avelumab for the treatment of metastatic merkel cell carcinoma for priority review

* Pfizer announced fda has accepted for priority review EMD Serono's Biologics license application for Avelumab Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐